Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

NCT07208981 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

169

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma(MZL)

Interventions

DRUG: Orelabrutinib
DRUG: Zebetuzumab
DRUG: Lenalidomide
DRUG: Bendamustine + Rituximab

Sponsor

The First Affiliated Hospital with Nanjing Medical University